LXEO Lexeo Therapeutics, Inc.
P/E
--
Forward P/E
6.35
Price/Sales
478.26
Beta
1.64
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Lexeo Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 18, 2026
Lexeo Therapeutics is projected to report a Q3 2026 net loss of $0.33 per share on zero revenue, while the stock currently trades at $3.32 against an average...
Lexeo Therapeutics reports third quarter 2026 results and positive interim Phase I/II data for LX2020
Lexeo Therapeutics reported third quarter 2026 financial results alongside positive interim data from its HEROIC-PKP2 trial for LX2020. The company has...
Lexeo Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026
Wall Street analysts expect Lexeo Therapeutics to report a Q3 2026 consensus net loss of $0.34 per share on zero revenue, while the stock currently trades...
Lexeo Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Lexeo Therapeutics is expected to report zero revenue and a consensus loss of $0.33 per share, while the current stock price of $3.14 trades well below the...